Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a technology-based company operating in two primary segments: laboratory services and therapeutic development. The laboratory services business provides technical laboratory and testing services, along with professional interpretation of results by licensed physicians. The therapeutic development business, operating as Fulgent Pharma, focuses on developing product candidates for cancer treatment using a novel nanoencapsulation and targeted therapy platform. The company's long-term vision is to evolve into a fully integrated precision medicine company.

The core business model for the laboratory services segment involves generating revenue from molecular testing, including precision diagnostics and anatomic pathology, and BioPharma services. Revenue is recognized upon delivery of a report to the ordering physician or customer, based on the established billing rate, adjusted for contractual and other factors to reflect the expected collectible amount. The therapeutic development segment has also begun generating BioPharma services revenue through the recently acquired ANP. Primary customer segments for laboratory services include Insurance, Institutional (hospitals, medical institutions, other laboratories, governmental bodies, and large corporations), and Patients who pay directly. A significant portion of revenue can be concentrated among a single large customer or a small number of larger customers.

The laboratory services business offers comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, supported by CLIA-licensed laboratories in the United States. This segment has invested significantly in digital pathology using artificial intelligence (AI) technology. Precision diagnostics testing services include next-generation sequencing (NGS) tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and other disease subtypes, as well as specialized oncology services utilizing flow cytometry, cytogenetic analysis, FISH, immunohistochemistry, molecular genetics, and NGS. BioPharma services involve testing and licensing to pharmaceutical or biotech companies, contract research organizations (CROs), or sponsored testing programs. The Picture platform is a patient-centric telemedicine platform for direct-to-consumer testing.

The therapeutic development business, Fulgent Pharma, acquired in 2022, is centered on a novel nano-drug delivery platform technology for water-insoluble or poorly soluble drugs. This platform aims to improve the pharmacokinetic profile, safety, and efficacy of encapsulated drugs for various diseases, particularly cancers. The company's pipeline includes FID-007 (nanoencapsulated paclitaxel) and FID-022 (nanoencapsulated SN38), both in clinical trials, and antibody-drug conjugates (ADCs) in pre-clinical development.

For the fiscal year ended December 31, 2025, total revenue was $322.671 million ¹, an increase of 14% from $283.470 million ² in 2024. Cost of revenue increased by 9% to $191.796 million ³ in 2025 from $176.255 million ⁴ in 2024. Gross profit for 2025 was $130.875 million ⁵, up 22% from $107.215 million ⁶ in 2024. The gross margin improved from 38% ⁷ in 2024 to 41% ⁸ in 2025. Operating loss for 2025 was ($91.096) million ⁹, compared to ($73.918) million ¹⁰ in 2024. Net loss attributable to Fulgent was ($60.513) million ¹¹ in 2025, an increase from ($42.708) million ¹² in 2024. Cash, cash equivalents, and marketable securities totaled approximately $705.5 million ¹³ as of December 31, 2025. Total debt is not explicitly stated as a single figure, but the company mentions corporate debt securities and municipal bonds as part of its marketable securities portfolio.

Year-over-year, revenue growth was primarily driven by a $22.727 million ¹⁴ increase in precision diagnostics, a $9.362 million ¹⁵ increase in anatomic pathology, and an $8.972 million ¹⁶ increase in BioPharma services. These gains were partially offset by a $2.307 million ¹⁷ decrease in COVID-19 revenue, which ceased material operations at the end of March 2023. Precision diagnostics growth was attributed to reproductive health services and legacy diagnostic offerings, while anatomic pathology benefited from the absence of prior year's weather disruptions and client losses. BioPharma services revenue increased due to the timing of service projects. Cost of revenue as a percentage of revenue decreased from 62.2% ¹⁸ to 59.4% ¹⁹, indicating improved efficiency. Non-U.S. revenue increased by $1.8 million ²⁰, or 7% ²¹, from $24.3 million ²² in 2024 to $26.1 million ²³ in 2025, primarily from China, Australia, and Canada.

Significant operational developments in 2025 included the launch of the Ultra Rapid Whole Genome Sequencing service. In December 2025, the company announced definitive agreements to acquire selected assets of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $55.5 million ²⁴ in cash, with closing expected in the first half of 2026. On July 9, 2025, Fulgent completed the acquisition of 100% of ANP Technologies, Inc., securing full ownership of patents previously licensed for FID-007 and FID-022. The company also purchased $106.3 million ²⁵ worth of Investment Tax Credits for $99.5 million ²⁶ in cash under the Inflation Reduction Act. In its therapeutic development, FID-007 completed enrollment for a Phase 1/1b clinical trial with 50 patients ²⁷ and began enrollment for a Phase 2 trial in recurrent or metastatic H&N squamous cell carcinoma in Q2 2024, expecting to complete it by early 2026. FID-022 completed its first dose level in December 2025 and second dose level in January 2026, commencing the third dose level in February 2026, with a goal to determine a maximum tolerated dose within the next year. ADC pre-clinical development also showed significant advancement.

Management anticipates reduced revenues from its largest laboratory customer in 2026, particularly through the second quarter of 2026, as this customer plans to perform certain tests and testing services internally. The company aims to offset this decline through the development of existing customers and the acquisition of new customers, including through the Bako Diagnostics and StrataDx acquisitions. However, the success of these offsetting efforts is not guaranteed.

A major growth area for the company is the expansion of its test menu and services. The company believes its ability to offer a broad and flexible testing menu, incorporating a large number of genes, provides a competitive advantage by offering comprehensive genetic information and improving variant detection rates. The launch of the Ultra Rapid Whole Genome Sequencing service in 2025 is an example of this expansion. The company plans to continue investing in research and development to innovate and expand the application of its testing platform.

Another significant growth vector is the therapeutic development business, Fulgent Pharma. The company is advancing its product candidates, FID-007 and FID-022, through clinical trials. FID-007, nanoencapsulated paclitaxel, completed enrollment for a Phase 1/1b clinical trial in the United States with 50 patients ²⁷ and began enrollment for a Phase 2 trial in recurrent or metastatic H&N squamous cell carcinoma in the second quarter of 2024. The Phase 2 trial is expected to complete by early 2026, with interim findings anticipated in June 2026 and a full data readout by the second half of 2027. Assuming favorable results, a Phase 3 registrational clinical trial for H&N squamous cell carcinoma is planned to initiate as early as the first half of 2027, with potential regulatory approval sought through the 505(b)(2) pathway. FID-022, nanoencapsulated SN38, is currently in a Phase 1/1b clinical trial, having completed its first dose level in December 2025 and second dose level in January 2026, with dosing for the third level commencing in February 2026. The goal is to determine a maximum tolerated dose within the next year, with plans to enroll 42 patients ²⁸ in this trial. Pre-clinical development of antibody drug conjugates (ADCs) using a novel linker and payload platform technology is also ongoing, with the goal of generating additional lead candidates for clinical studies.

Operationally, the company's gross margin increased from 38% ⁷ in 2024 to 41% ⁸ in 2025, driven by increased revenue, efforts to optimize cost structures, and efficiency gains from investments in scaling and centralizing lab operations. The company expects research and development expenses to continue increasing in absolute dollars, particularly for the therapeutic development segment, due to incremental expenses associated with product candidates in clinical trials. Selling and marketing expenses are also expected to increase in absolute dollars, driven by investments in expanding the sales team, implementing new strategies, and increasing the overall scope of marketing efforts. General and administrative expenses are anticipated to rise as the company scales its operations and incurs costs related to operating as a public company.

The company relies on a limited number of suppliers for laboratory reagents, sequencers, and other equipment. While alternative suppliers are believed to exist for most needs, transitioning to new suppliers would be time-consuming and expensive. The acquisition of ANP Technologies, Inc. in July 2025 secured full ownership of patents previously licensed, enhancing control over the development and commercialization of related therapeutic candidates. The company also purchased $106.3 million ²⁵ worth of Investment Tax Credits for $99.5 million ²⁶ in cash in 2025.

The company faces structural headwinds and execution risks, including the potential for significant fluctuations in operating results due to factors such as the mix of tests delivered, customer and payor mix, and general price degradation. The concentration of revenue from a single large customer, which is expected to decline in 2026, poses a risk. The company also faces intense competition in both its laboratory services and therapeutic development businesses, with many competitors having greater resources and market penetration. The development of new tests and product candidates is time-consuming, costly, and uncertain, with potential for delays or failures in clinical trials.

Geographically, the company's international operations expose it to varied and complex foreign and international laws and regulations, including privacy and data protection regulations, tax laws, tariffs, and trade policies. The joint venture in China is subject to risks related to PRC laws and regulations and changes in relations between the United States and China. The company is also subject to U.S. economic and trade sanctions.

The company faces material risks across several domains. Macroeconomic risks include the potential for inflation to materially increase costs of clinical trials, research, development, and administration, potentially outpacing expectations and accelerating cash usage. Competitive risks are intense, with numerous established companies in both laboratory services and therapeutic development possessing longer operating histories, larger customer bases, greater brand recognition, and substantially greater financial and R&D resources, which could lead to more aggressive pricing or faster product development. Regulatory risks are significant and complex, with evolving federal and state laws governing clinical laboratory tests, medical devices, and data privacy, including HIPAA, HITECH, and state-specific laws like the California Confidentiality of Medical Information Act and the California Consumer Privacy Act, as amended by the California Privacy Rights Act. Non-compliance with these laws, or with foreign privacy laws like GDPR, could result in substantial civil and criminal penalties, fines up to approximately $2.1 million ²⁹ per violation per calendar year for HIPAA, and up to EUR 35 million ³⁰ or 7% ³¹ of worldwide annual turnover for GDPR infringements. The company is also subject to ongoing governmental audits and investigations, including a HRSA audit and DOJ Civil Investigative Demands (CIDs) related to COVID-19 testing reimbursements and alleged false claims, the outcomes of which are uncertain and could result in material refunds or settlements. Operational risks include reliance on a limited number of suppliers, with Illumina Inc. being the sole supplier for next-generation sequencers and reagents, and potential disruptions to laboratory operations from facility inoperability or delivery service interruptions. The company's development and use of AI also presents risks related to data security, compliance with emerging regulations, and potential for legal or reputational harm. Geopolitical risks stem from international operations, including potential trade wars, tariffs, and political instability in regions like Ukraine and the Middle East, which could disrupt supply chains and limit market penetration.

Management's message to shareholders emphasizes the company's identity as a technology-based entity with established laboratory services and a growing therapeutic development business, driven by a mission of flexibility and affordability in diagnostic and genetic testing. The long-term strategic vision is to transform into a fully integrated precision medicine company. Management highlighted the 2025 revenue of $322.671 million ¹ and a net loss attributable to Fulgent of ($60.513) million ¹¹. Key strategic priorities include diversifying the customer base and capturing new customers to offset an anticipated decline in revenue from a significant laboratory customer in 2026, particularly through the second quarter of 2026. Another priority is the continued investment in research and development for both laboratory services, such as the Ultra Rapid Whole Genome Sequencing service, and the therapeutic development segment, advancing product candidates like FID-007 and FID-022 through clinical trials. The acquisition of ANP Technologies, Inc. in July 2025 and the planned acquisitions of Bako Diagnostics and StrataDx are integral to these strategic objectives, aiming to enhance control over intellectual property and expand market presence.